Recently, the results of the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS, targeting the interleukin-1β) trial show conclusive proof that reduction of inflammation by inhibiting the IL-1β pathway activation can significantly lower coronary artery disease morbidity and mortality [20]. This evidence concerns the gene IL1B and Venous thrombosis.